Literature DB >> 15682306

Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.

Yong Zhang1, Eduardo R Butelman, Stefan D Schlussman, Ann Ho, Mary Jeanne Kreek.   

Abstract

RATIONALE: Salvinorin A is a naturally occurring hallucinogen derived from the plant Salvia divinorum. Salvinorin A is also a potent and selective kappa opioid receptor agonist in vitro. It has been shown that kappa agonists decrease dopamine levels in the caudate putamen and nucleus accumbens and cause conditioned place aversion in rodents.
OBJECTIVES: To study the effects of salvinorin A on basal dopamine levels in the caudate putamen and nucleus accumbens, and to determine whether salvinorin A induces conditioned place preference or aversion and changes in locomotor activity in the mouse.
METHODS: In the first experiment, changes in dopamine levels in these brain regions after administration of salvinorin A were measured with in vivo microdialysis. In the second experiment, we examined whether salvinorin A led to conditioned place preference or aversion, and changes in locomotor activity during conditioning sessions.
RESULTS: The higher doses of salvinorin A studied (1.0 mg/kg and 3.2 mg/kg, i.p.) significantly decreased dopamine levels in the caudate putamen, but not in the nucleus accumbens, and this effect was completely blocked by pre-injection with 10 mg/kg of the kappa opioid receptor antagonist nor-binaltorphimine. The same doses of salvinorin A caused conditioned place aversion and decreased locomotor activity.
CONCLUSIONS: The inhibitory effect of salvinorin A on striatal dopamine levels may contribute to its induction of conditioned place aversion and decreases in locomotion in mice. These findings are consistent with the in vitro characterization of salvinorin A as a kappa opioid receptor agonist. It is of interest that a compound such as salvinorin A, that lowers striatal dopamine levels and leads to conditioned place aversion in rodents, is self-administered by humans under certain conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682306     DOI: 10.1007/s00213-004-2087-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Effect of acute binge cocaine on levels of extracellular dopamine in the caudate putamen and nucleus accumbens in male C57BL/6J and 129/J mice.

Authors:  Y Zhang; S D Schlussman; A Ho; M J Kreek
Journal:  Brain Res       Date:  2001-12-27       Impact factor: 3.252

2.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

3.  Distribution of kappa opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study.

Authors:  A M DePaoli; K M Hurley; K Yasada; T Reisine; G Bell
Journal:  Mol Cell Neurosci       Date:  1994-08       Impact factor: 4.314

4.  Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice.

Authors:  A V Kuzmin; S Semenova; M A Gerrits; E E Zvartau; J M Van Ree
Journal:  Eur J Pharmacol       Date:  1997-03-05       Impact factor: 4.432

5.  Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice.

Authors:  N T Jamensky; C Gianoulakis
Journal:  Alcohol Clin Exp Res       Date:  1997-11       Impact factor: 3.455

6.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Authors:  Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2004-01-08       Impact factor: 4.030

9.  Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats.

Authors:  Anja Meyer; Andreas Mayerhofer; Karl-Artur Kovar; Werner J Schmidt
Journal:  Neurosci Lett       Date:  2002-09-27       Impact factor: 3.046

10.  Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study.

Authors:  I M Maisonneuve; M J Kreek
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

View more
  73 in total

1.  Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.

Authors:  S Stevens Negus; Robert O'Connell; Ember Morrissey; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2011-11-29       Impact factor: 4.030

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 3.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 4.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

Review 5.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

6.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

Review 7.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 8.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.

Authors:  Abigail G Schindler; Daniel I Messinger; Jeffrey S Smith; Haripriya Shankar; Richard M Gustin; Selena S Schattauer; Julia C Lemos; Nicholas W Chavkin; Catherine E Hagan; John F Neumaier; Charles Chavkin
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.